Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypothalamic Obesity Clear all
Completed Phase 2 Interventional

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

NCT02063295
View directory record Official record
Conditions
Obesity, Over-weight, Hypothalamic Injury, Craniopharyngioma
Interventions
ZGN-440 sterile diluent, ZGN-440 for injectable suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Saint Paul, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
LB54640, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation Effects on Weight Change and Metabolic Rate

NCT01933113
View directory record Official record
Conditions
Obesity
Interventions
Deep Brain Stimulation of the Lateral Hypothalamic Area
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 6, 2026, 1:56 PM EDT
Enrolling by invitation Phase 2 Interventional

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

NCT07156578
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Bivamelagon
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of Setmelanotide in Hypothalamic Obesity

NCT04725240
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
San Diego, California • Gainesville, Florida • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 6, 2026, 1:56 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 1:56 PM EDT
Terminated No phase listed Observational

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

NCT00504218
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 24 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 6, 2026, 1:56 PM EDT
Terminated No phase listed Observational

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

NCT00078091
View directory record Official record
Conditions
Bardet-Biedl Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 6, 2026, 1:56 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Results available

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

NCT03746522
View directory record Official record
Conditions
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
San Diego, California • Springfield, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 6, 2026, 1:56 PM EDT
Terminated No phase listed Observational

Evaluation of Patients With Endocrine-Related Conditions

NCT00005664
View directory record Official record
Conditions
Adrenal Insufficiency, Pituitary Neoplasm, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 6, 2026, 1:56 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

NCT01237041
View directory record Official record
Conditions
Obesity, Short Stature, Growth Hormone Deficiency
Interventions
Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg, Dose-Establishing Study 2 Niacin 500mg
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 14 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does What You Eat Affect Your Brain

NCT05626907
View directory record Official record
Conditions
Gliosis, Obesity, Eating
Interventions
Diet modification #1, Diet modification #2, Diet modification #3
Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 6, 2026, 1:56 PM EDT
Recruiting No phase listed Observational

International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry

NCT03135730
View directory record Official record
Conditions
ROHHAD, Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation
Interventions
ROHHAD
Genetic
Lead sponsor
Ilya Khaytin
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2039
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 6, 2026, 1:56 PM EDT
Withdrawn Phase 2 Interventional

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

NCT05147415
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Placebo, Tesomet
Other · Drug
Lead sponsor
Saniona
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 6, 2026, 1:56 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Not applicable Interventional

The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

NCT00688987
View directory record Official record
Conditions
Obesity, Addison's Disease
Interventions
Hydrocortisone, Isocaloric Diet
Drug · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Sep 6, 2026, 1:56 PM EDT
Terminated Phase 4 Interventional Results available

Body Composition and Adipose Tissue in HIV

NCT03226821
View directory record Official record
Conditions
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
Interventions
Tesamorelin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 68 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 6, 2026, 1:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hormone Dynamics and Bone Mineral Density in Anorexia Nervosa v. Hypothalamic Amenorrhea

NCT00556036
View directory record Official record
Conditions
Anorexia Nervosa, Hypothalamic Amenorrhea, Obesity
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Phase 4 Interventional

Pediatric Hypothalamic Obesity

NCT00076362
View directory record Official record
Conditions
Obesity
Interventions
Sandostatin LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of Setmelanotide

NCT06596135
View directory record Official record
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

NCT05194124
View directory record Official record
Conditions
Bardet-Biedl Syndrome, POMC Deficiency
Interventions
Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 6, 2026, 1:56 PM EDT
Recruiting No phase listed Observational

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

NCT02602769
View directory record Official record
Conditions
Childhood Obesity, Morbid Obesity
Interventions
Transcriptome profiling
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 20 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Boston, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 6, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

NCT01484873
View directory record Official record
Conditions
Obesity, Overweight, Craniopharyngioma
Interventions
Exenatide
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 6, 2026, 1:56 PM EDT